| Literature DB >> 27987438 |
María Arriba1, Juan L García2, Daniel Rueda3, Jessica Pérez2, Lorena Brandariz4, Oana A Nutu4, Laura Alonso4, Yolanda Rodríguez5, Miguel Urioste6, Rogelio González-Sarmiento2, José Perea7.
Abstract
AIM: To investigate whether chromosomal instability (CIN) is associated with tumor phenotypes and/or with global genomic status based on MSI (microsatellite instability) and CIMP (CpG island methylator phenotype) in early-onset colorectal cancer (EOCRC).Entities:
Mesh:
Year: 2016 PMID: 27987438 PMCID: PMC5166699 DOI: 10.1016/j.neo.2016.11.006
Source DB: PubMed Journal: Neoplasia ISSN: 1476-5586 Impact factor: 5.715
Fig. 1Unsupervised hierarchical clustering based on the genomic instability profiles of the studied tumors. The studied samples were stratified into two main clusters (A, B) and four secondary clusters (A1, A2, B3, B4) according to the similarity of the CNAs detected.
Fig. 2Kaplan–Meier survival plots: (A) Comparison of the DFS between the two main clusters; (B) comparison of the DFS between the four subclusters; (C) comparison of the OS between the two main clusters; (D) comparison of the OS between the four subclusters. Note the significantly higher proportion of tumor recurrence within the cluster A.
Clinicopathological correlation of the different subgroups obtained by unsupervised hierarchical clustering analysis
| Cluster A1 | Cluster A2 | Cluster B3 | Cluster B4 | ||
|---|---|---|---|---|---|
| No. of tumors | 25 | 13 | 10 | 12 | |
| 36–45 years old | 19 | 10 | 9 | 11 | NS |
| <36 years old | 6 (54.5%) | 3 (27.3%) | 1 (9.1%) | 1 (9.1%) | |
| Location | |||||
| Right colon | 5 (20%) | 5 (38.4%) | 1 (10%) | 1 (8.3%) | |
| Left colon | 15 (60%) | 4 (30.8%) | 7 (70%) | 6 (50%) | NS |
| Rectum | 5 (20%) | 4 (30.8%) | 2 (20%) | 5 (41.7%) | |
| Histology | |||||
| Adenocarcinoma | 22 (88%) | 7 (53.8%) | 9 (90%) | 11 (91.7%) | 0.034 |
| Malignant adenoma | 3 (12%) | 6 (46.2%) | 1 (10%) | 1 (8.3%) | |
| T. differentiation: | |||||
| High | 10 (45.5%) | 3 (42.9%) | 4 (44.4%) | 2 (18.2%) | |
| Moderate | 8 (36.4%) | 4 (57.1%) | 5 (55.6%) | 9 (81.8%) | NS |
| Low | 4 (18.1%) | - | - | - | |
| Mucin production | 7 (31.8%) | 1 (14.3%) | 3 (33.3%) | 2 (18.2%) | NS |
| “Signet ring” cells | 1 (4.5%) | - | 1 (11.1%) | - | NS |
| TNM stage | |||||
| I | 6 (24%) | 6 (46.2%) | 2 (20%) | 3 (25%) | |
| II | 9 (36%) | 4 (30.8%) | 7 (70%) | 1 (8.3%) | NS |
| III | 5 (20%) | 1 (7.6%) | 1 (10%) | 3 (25%) | |
| IV | 5 (20%) | 2 (15.4%) | - | 5 (41.7%) | |
| Average No. of polyps | 3.76 [1.00] | 6.00 [4.00] | 2.40 [2.00] | 1.33 [0.00] | NS[2] |
| Synchronous T. | 2 (8%) | 1 (7.7%) | - | - | NS |
| Metachronous T. | - | 2 (15.4%) | - | - | NS |
| OS ± SD | 87.12 ± 50.85 | 99.08 ± 63.18 | 86.10 ± 10.03 | 59.50 ± 36.07 | NS[3] |
| DFS ± SD | 72.60 ± 53.90 | 78.38 ± 65.68 | 84.50 ± 9.48 | 51.42 ± 44.26 | NS[3] |
| T. recurrence | 5 (20%) | 2 (15.4%) | - | - | NS |
| Mortality | 7 (28%) | 3 (23.1%) | - | 4 (33.3%) | NS |
| Sporadic | 13 (52%) | 3 (23.1%) | 5 (50%) | 6 (50%) | |
| Familial aggregation | 9 (36%) | 6 (46.2%) | 1 (10%) | 4 (33.3%) | NS |
| Amsterdam II positive | 3 (12%) | 4 (30.7%) | 4 (40%) | 2 (16.7%) | |
| Lynch syndrome | 2/7 (28.6%) | 3/7 (42.8%) | 2/7 (28.6%) | - | NS |
Data shown in brackets represent median values. [1]Statistical comparison was performed using Pearson's Chi Square (χ2) test.[2] Statistical comparison was performed using the Kruskal-Wallis test. [3]Statistical comparison was performed using analysis of variance (ANOVA). ⁎DFS: Disease-free survival. †No.: Number. ‡NS: Not significant. §OS: Overall survival. ᵟSD: Standard deviation. ᵠT.: Tumor.
Global distribution of MSI and CIMP among the different subgroups obtained by unsupervised hierarchical clustering analysis
| Cluster A1 | Cluster A2 | Cluster B3 | Cluster B4 | ||
|---|---|---|---|---|---|
| No. of tumors | 25 | 13 | 10 | 12 | - |
| MSI | 2 (8%) | 3 (23.1%) | 5 (50%) | - | 0.007 |
| Expression of MMR: | |||||
| Normal | 23 | 10 | 5 | - | 0.007 |
| Absence | 2 | 3 | 5 | - | |
| Lynch Syndrome | 2 | 3 | 2 | - | NS |
| MMR genes affected: | |||||
| | 1 | - | - | - | - |
| | - | 3 | 1 | - | |
| | 1 | - | 1 | - | |
| - | - | - | 1 (100%) | - | |
| CIMP-High | 7 (28%) | 4 (30.8%) | - | 1 (8.3%) | NS |
| CIMP-Low/0 | 18 (72%) | 9 (69.2%) | 10 (100%) | 11 (91.7%) | |
| Mol. classification: | |||||
| MSI/CIMP-High | 1 (4%) | 2 (15.4%) | - | - | 0.004 |
| MSI/CIMP-Low/0 | 1 (4%) | 1 (7.7%) | 5 (50%) | - | |
| MSS/CIMP-High | 6 (24%) | 2 (15.4%) | - | 1 (8.3%) | |
| MSS/CIMP-Low/0 | 17 (68%) | 8 (61.5%) | 5 (50%) | 11 (91.7%) |
Statistical comparison was performed using Pearson's Chi Square (χ2) test. ⁎CIMP: CpG island methylator phenotype. †MMR: Mismatch repair. ‡Mol.: Molecular. §MSI: Microsatellite instability. ᵟMSS: Microsatellite instability. ᵠNo.: Number. ᵜNS: Not significant.
Global description and comparison of genomic instabilities observed for the different subgroups obtained by unsupervised hierarchical clustering analysis
| Cluster A1 | Cluster A2 | Cluster B3 | Cluster B4 | ||
|---|---|---|---|---|---|
| No. of tumors | 25 | 13 | 10 | 12 | - |
| GII total Mean [SD] | 0.40010 [0.26115] | 0.11184 [0.21733] | 0.39149 [0.27826] | 0.30166 [0.31020] | 0.017 |
| Average CNAs/tumor | 135.16 (118.00) | 45.69 (42.00) | 95.30 (104.00) | 68.50 (32.50) | 0.048 |
| GII gains Mean [SD] | 0.18963 [0.10511] | 0.03881 [0.09584] | 0.19251 [0.22203] | 0.15778 [0.15866] | 0.016 |
| Average CNAs gained/tumor: | 72.32 (58.00) | 11.38 (7.00) | 39.10 (29.50) | 32.42 (14.50) | 0.0001[2] |
| > 1 Mb | 58.28 (48.00) | 6.08 (4.00) | 26.50 (18.00) | 24.42 (7.50) | 0.0001[2] |
| < 1 Mb | 14.04 (11.00) | 5.31 (5.00) | 11.60 (11.50) | 8.00 (4.50) | 0.047[2] |
| GII losses Mean [SD] | 0.21047 [0.21216] | 0.07303 [0.14926] | 0.19898 [0.11768] | 0.14388 [0.16880] | NS[2] |
| Average CNAs lost/tumor: | 62.84 (58.00) | 34.31 (42.00) | 56.20 (72.00) | 36.08 (16.50) | NS |
| > 1 Mb | 42.12 (20.00) | 11.46 (14.00) | 40.80 (51.00) | 23.75 (12.00) | 0.024[2] |
| < 1 Mb | 20.72 (15.00) | 22.85 (24.00) | 15.40 (15.00) | 12.33 (3.00) | NS |
| Average of aneuploidy: | 2.83 (3.00) | 1.46 (0.00) | 4.44 (4.00) | 4.08 (3.00) | NS |
| Whole chromosomes gained | 1.76 (2.00) | 0.76 (0.00) | 1.80 (0.50) | 2.58 (1.50) | 0.010[2] |
| Whole chromosomes lost | 0.96 (0.00) | 0.69 (0.00) | 2.20 (3.00) | 1.50 (1.00) | NS[2] |
| CIN- tumors | 4 (20%) | 10 (50%) | 3 (15%) | 3 (15%) | 0.003[3] |
| CIN+ tumors | 9 (39.1%) | 2 (8.7%) | 6 (26.1%) | 6 (26.1%) | |
| MACS | 12 (70.6%) | 1 (5.9%) | 1 (5.9%) | 3 (17.6%) |
Data shown in parentheses represent median values. Tumors with more than 3 whole chromosomes affected were considered as CIN+; tumors with 1–3 whole chromosomes affected were considered as MACS; tumors with no whole chromosome affected were considered as CIN-. [1]Statistical comparison was performed using analysis of variance (ANOVA). [2]Statistical comparison was performed using the Kruskal-Wallis test. [3]Statistical comparison was performed using Pearson's Chi Square (χ2) test. ⁎CIN: Chromosomal instability. †CNAs: Copy number alterations. ‡GII: Genomic instability index. §MACS: Microsatellite and chromosome-stable. ᵟMb: Megabasepairs. ᵠNo.: Number. ᵜNS: Not significant. ᶘSD: Standard deviation.
Fig. 3Algorithm by which tumors may be categorized according to their genomic status based on CIN, MSI and CIMP. The CIMP-High tumors were mostly contained within clusters A1 or A2 depending on the CIN degree, whereas the CIMP-Low/0 tumors were mostly contained within clusters B3 or B4 depending on the MSI status.